Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/40002
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDomínguez, Àngela
dc.contributor.authorSoldevila, Núria
dc.contributor.authorToledo, Diana
dc.contributor.authorTorner, Núria
dc.contributor.authorForce, Luis
dc.contributor.authorPérez, María José
dc.contributor.authorMartín, Vicente
dc.contributor.authorRodríguez-Rojas, Lourdes
dc.contributor.authorAstray, Jenaro
dc.contributor.authorEgurrola, Mikel
dc.contributor.authorSanz, Francisco
dc.contributor.authorCastilla, Jesús
dc.date.accessioned2019-07-01T06:29:30Z-
dc.date.available2019-07-01T06:29:30Z-
dc.date.issued2017
dc.identifier.citationPLoS ONE.2017;(12)2:e0171943
dc.identifier.urihttps://hdl.handle.net/20.500.12530/40002-
dc.description.abstractPneumococcal pneumonia is a serious cause of morbidity and mortality in the elderly, but investigation of the etiological agent of community-acquired pneumonia (CAP) is not possible in most hospitalized patients. The aim of this study was to estimate the effect of pneumococcal polysaccharide vaccination (PPSV23) in preventing CAP hospitalization and reducing the risk of intensive care unit admission (ICU) and fatal outcomes in hospitalized people aged ≥65 years. We made a multicenter case-control study in 20 Spanish hospitals during 2013-2014 and 2014-2015. We selected patients aged ≥65 years hospitalized with a diagnosis of pneumonia and controls matched by sex, age and date of hospitalization. Multivariate analysis was performed using conditional logistic regression to estimate vaccine effectiveness and unconditional logistic regression to evaluate the reduction in the risk of severe and fatal outcomes. 1895 cases and 1895 controls were included; 13.7% of cases and 14.4% of controls had received PPSV23 in the last five years. The effectiveness of PPSV23 in preventing CAP hospitalization was 15.2% (95% CI -3.1-30.3). The benefit of PPSV23 in avoiding ICU admission or death was 28.1% (95% CI -14.3-56.9) in all patients, 30.9% (95% CI -32.2-67.4) in immunocompetent patients and 26.9% (95% CI -38.6-64.8) in immunocompromised patients. In conclusion, PPSV23 showed a modest trend to avoidance of hospitalizations due to CAP and to the prevention of death or ICU admission in elderly patients hospitalized with a diagnosis of CAP.
dc.language.isoeng
dc.rightsopenAccess-
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshCase-Control Studies
dc.subject.meshCommunity-Acquired Infections
dc.subject.meshFemale
dc.subject.meshHospitalization
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshPneumococcal Vaccines
dc.subject.meshPneumonia, Pneumococcal
dc.subject.meshSpain
dc.subject.meshVaccination
dc.titleEffectiveness of 23-valent pneumococcal polysaccharide vaccination in preventing community-acquired pneumonia hospitalization and severe outcomes in the elderly in Spain.
dc.typeArtículo
dc.identifier.pubmedID28187206
dc.format.volume12
dc.format.pagee0171943
dc.identifier.e-issn1932-6203
dc.identifier.journalPloS one
dc.identifier.doi10.1371/journal.pone.0171943
dc.format.number2
dc.identifier.pmcPMC5302444
dc.pubmedtypeEvaluation Studies
dc.pubmedtypeJournal Article
dc.pubmedtypeMulticenter Study
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. U. Ramón y Cajal > Artículos

Files in This Item:
File Description SizeFormat 
PMC5302444.pdf820.93 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.